Clinical Trial Update: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating second-line treatment with FOLFIRI or modified FOLFIRI plus Veliparib in metastatic pancreatic cancer; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-09-29